Exelixis (EXEL) said a phase 3 study showed its cabozantinib drug reduced the risk of disease progression or death by 50% compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors
The study involved 116 patients with median progression-free survival of 8.5 months with cabozantinib compared with 5.6 months with placebo, the company said Friday in a statement.
The results "demonstrate the benefits of cabozantinib across a wide range of patients with neuroendocrine tumors and further underscore the potential of cabozantinib to become a much-needed new option," Exelixis Chief Medical Officer Amy Peterson said in the statement.
The US Food and Drug Administration is currently reviewing a supplemental new drug application for cabozantinib, the company said.
Shares of Exelixis fell 5.2% in late Friday trading. Earlier, Oppenheimer downgraded the stock to perform from outperform and cut the price target to $33 from $41.
Price: 32.34, Change: -1.79, Percent Change: -5.24
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.